Carfilzomib in ALL

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

5 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

CHOP, in collaboration with Onyx Therapeutics, Inc., is conducting a study for children and young adults up to 21 years old, with relapsed or refractory acute lymphoblastic leukemia. This clinical trial is adding the study drug, Carfilzomib, to a standard relapse chemotherapy regimen. For more information about this study, including specific eligibility criteria, please visit clinicaltrials.gov and search for "NCT02303821". To hear more about this and other available trails or get any questions answered please contact our Cancer Intake Specialist by phone at 267-426-0762 or email [email protected]

Eligibility & Criteria

IRB #:
21-018966
Official Title:
Phase 1b/2 Study Of Carfilzomib In Combination With Induction Chemotherapy In Children With Relapsed Or Refractory Acute Lymphoblastic Leukemia
Study Phase:
Phase II
Gender:
All
Study Categories:

Visit Criteria

Participants will receive carfilzomib via intravenous (IV) infusion. Study visits will include the following assessments: blood draws; optional tissue collection (left-over or extra) will be collected if a biopsy is performed as standard of care, and optional saliva collection. Existing tissue samples may also be used in this study.

Leader
Susan R. Rheingold

Susan R. Rheingold, MD